|
 |
|
|
|||
 |
 
  
|
 |
|
 Oct. 26, 2012 Source: Bayer HealthCare news release Bayer has received market authorization for BaytrilŪ 100 (enrofloxacin) injectable solution for treating swine respiratory disease (SRD). This life-saving antimicrobial is bactericidal, killing the major culprits responsible for SRD in swine: Actinobacillus pleuropneumoniae, Pasteurella multocida and Haemophilus parasuis. BaytrilŪ 100 is concentration-dependent, not time-dependent, delivering therapeutic drug concentrations to the lung tissues within two hours of a single subcutaneous dose. By concentrating where it is needed, BaytrilŪ 100 achieves pharmacokinetic and pharmacodynamic drug ratios associated with both the reduction of bacterial resistance selection and improved treatment success. Available to veterinarians since 2004 for treating recurring respiratory disease in high risk feedlot cattle, Canadian swine veterinarians can now take advantage of this new tool to help them in their fight against SRD. Pneumonia can reduce pig growth rates5 by as much as eight percent so veterinarians need products that work quickly to get their patients back to health. "Left untreated, respiratory disease in pigs causes lung damage and increases mortality, impacting the bottom line," said Dr. Bruce Kilmer, Bayer HealthCare, Animal Health's Director of Technical Services & Regulatory Affairs. "Researchers6 have found that SRD can increase feed costs by adding up to six additional days to market. BaytrilŪ 100 has been trusted by veterinarians for years and is highly effective for the treatment of SRD." BaytrilŪ 100's proven efficacy in low volume with easy syringeability encourages successful treatment. For swine, the ready-to-use, injectable antimicrobial solution is administered as a single-dose therapy. BaytrilŪ 100 should not be used as a mass medication. The choice of BaytrilŪ 100 as the most appropriate treatment should be confirmed by clinical experience supported, where possible, by pathogen culture and drug susceptibility testing. Enrofloxacin has demonstrated in vivo activity against Actinobacillus pleuropneumoniae, Pasteurella multocida and Haemophilus parasuis, the major pathogenic bacteria associated with SRD. Enrofloxacin is active in vitro against gram-negative and gram-positive bacteria. For more information on BaytrilŪ 100, contact the Bayer HealthCare, Animal Health technical service line at 1-888-663-5326, or visit www.animalhealth.bayer.ca Please refer to the product label for precautions and warnings. Tweet |
|
|
|
|
|
|
|
|
 |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
